• Korean Journal of Clinical Laboratory Science
• /
• v.55 no.4
• /
• pp.253-260
• /
• 2023

The germanium-68/gallium-68 (⁶⁸Ge/⁶⁸Ga) generator has high spatial utilization and requires little maintenance, making it economical and easy to produce. Thus, the frequency of use of ⁶⁸Ga radiopharmaceuticals is rapidly increasing worldwide. Therefore, this study attempted to develop an automated synthesizer for the routine clinical application of ⁶⁸Ga radiopharmaceuticals. The automated synthesizer was based on a fixed tubing system and the structure was designed after adjusting the position of the parts to reflect the synthesis method. Using various components that can be supplied in Korea, the automated synthesizer was manufactured at a much lower price cost than that of a commercialized automated synthesizer sold by companies. ⁶⁸Ga-DOTA-[Tyr3]-octreotide (⁶⁸Ga-DOTATOC) was synthesized to evaluate the performance of the automated synthesizer. ⁶⁸Ga-DOTATOC could be synthesized with about 65% of non-decay corrected yield, and the synthesized ⁶⁸Ga-DOTATOC met all quality control standards. We have synthesized ⁶⁸Ga-DOTATOC more than 100 times, and only faced a few problems caused by mechanical errors. In this study, we successfully developed a simple automated synthesizer for ⁶⁸Ga radiopharmaceuticals with high reproducibility. As various ⁶⁸Ga radiopharmaceuticals have recently been developed, it is expected that the automated synthesizer developed in this study will be useful for routine clinical use.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.3 no.2
• /
• pp.85-90
• /
• 2017

$^{68}Ga-PET$ is of growing importance in the practice of nuclear medicine diagnostic imaging for neuroendocrine tumors as well as prostate cancers. Following this interests, we herein present the radiosynthesis process of [$^{68}Ga$]edotreotide ([$^{68}Ga$]DOTA-TOC) based on the fully automated procedure for clinical doses that can be provided the reduction of radiation exposure and high reproducibility. The quality controls of clinical doses in compliant with European Pharmacopoeia are also discussed.